The Hasselt-based company Complix entered into a collaboration with Merck (MSD), for development of Alphabodies™. Alphabodies™ are synthetic cell-penetrating antibodies (CPABs) for the treatment of cancer.
Complix will deliver CPABs to Merck against two intracellular cancer targets. Merck will fund these research activities and has the option to obtain the exclusive rights for the resulting compounds. Complix will receive an upfront payment, potential milestones of up to 280 million dollars and royalties.
Mark Vaeck, CEO of Complix says: “This collaboration highlights the potential of our unique CPAB platform, delivering game changing biotherapeputics for the treatment of cancer. I am very much looking forward to working with the team of MSD.”
